Byetta Amylin Pharmaceuticals / Eli Lilly & Co. - Treatment for Type 2 Diabetes

Byetta is the first in a new class of drugs called incretin mimetics, formulated for self-administration as a fixed dose, subcutaneous injection given prior to the morning and evening meals. Byetta is indicated as as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea, two common oral diabetes medications.

Posted: April 2005

Related Articles:

Byetta (exenatide) FDA Approval History

View comments

Hide
(web1)